Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy (Globe Newswire)
Solid Biosciences Inc., which acquired UF startup AavantiBio, announced that the European Commission has granted Orphan Drug designation to SGT-003 for treating Duchenne muscular dystrophy.
UF’s HiPerGator Drives FNN’s AI Wildfire Detection in Verizon Prize Recognition (HPC Wire)
UF Innovate | Accelerate resident client FNN won Verizon’s Disaster Resilience Prize for using AI to enhance disaster response and grid resilience.
UF Innovate | Accelerate Earns Four Honors at InBIA ICBI Conference Awards Ceremony (Global Innovation Institute)
The UF Innovate | Accelerate program was recognized at the InBIA International Business Innovation Association ICBI Conference Awards Ceremony, earning four major honors.
Is Space Biotech Building Its Apps Before Its Operating System? (Hyper Frame)
UF Innovate | Accelerate resident client Aloft Biotechnologies is developing a novel microgravity bioreactor using air-film technology to enable scalable cell culture, highlighting the critical role of hardware innovation in the future of orbital biotechnology.
Synvitta Diagnostics Announces Bold Mission To Advance Multiplex Diagnostic Testing (Alachua Chronicle)
UF Innovate | Accelerate resident client Synvitta Diagnostics, Inc., a biotechnology company developing next-generation diagnostic solutions, announced a strategic partnership between Mitch Glaeser, Co-Founder and Chief Executive Officer, and Rainara Almeida, M.Sc., Co-Founder and Chief Scientific Officer.
Pheronym Awarded $378,000 NSF Phase IIB Supplemental Funding To Accelerate Commercialization and Scale Manufacturing (EIN Presswire)
UF Innovate | Accelerate alum Pheronym, an ag-biotech pest control company, announced it has been awarded $378,000 in National Science Foundation (NSF) SBIR Phase IIB supplemental funding.
Inside LPRC IMPACT 2026
A cool opening-night reception at UF Innovate | The Hub and the LPRC INNOVATE labs marked the start of a learning-packed few days at the 2026 LPRC IMPACT Conference, March 17-19.
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia (Globe Newswire)
UF Innovate | Accelerate graduate Oragenics has received final ethics approval in Australia to begin its Phase IIa clinical trial of ONP-002, an intranasal therapy being developed to treat concussion and mild traumatic brain injury.
Verizon Is Investing in a New Generation of Life-Saving Disaster Resilience Technology (Verizon)
UF Innovate | Accelerate resident client FNN has been selected as one of four innovators in the 2025 Verizon Disaster Resilience Prize, a $1 million program supporting technologies that help communities better prepare for and respond to natural disasters.
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy (Globe Newswire)
UF Innovate | Accelerate graduate Oragenics, Inc. outlined its 2026 milestones as it advances ONP-002, a novel intranasal neurosteroid in clinical development for concussion and mild traumatic brain injury.